Investigational Drug Information for RG1662
✉ Email this page to a colleague
What is the development status for investigational drug RG1662?
RG1662 is an investigational drug.
There have been 9 clinical trials for RG1662.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 5th 2014.
The most common disease conditions in clinical trials are Down Syndrome, Syndrome, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].
There are thirteen US patents protecting this investigational drug and one hundred and sixty-one international patents.
Summary for RG1662
| US Patents | 13 |
| International Patents | 161 |
| US Patent Applications | 35 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2014-05-05) |
| Vendors | 33 |
Recent Clinical Trials for RG1662
| Title | Sponsor | Phase |
|---|---|---|
| A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age | Hoffmann-La Roche | Phase 2 |
| Basmisanil Positron Emission Tomography Study in Japanese Volunteers | Hoffmann-La Roche | Phase 1 |
| A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects | Hoffmann-La Roche | Phase 1 |
Clinical Trial Summary for RG1662
Top disease conditions for RG1662
Top clinical trial sponsors for RG1662
US Patents for RG1662
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RG1662 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| RG1662 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| RG1662 | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| RG1662 | See Plans and Pricing | Compositions and methods for neurological diseases | Coda Biotherapeutics, Inc. (South San Francisco, CA) | See Plans and Pricing |
| RG1662 | See Plans and Pricing | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (Nutley, NJ) | See Plans and Pricing |
| RG1662 | See Plans and Pricing | Process for the preparation of isoxazolyl-methoxy nicotinic acids | Hoffman-La Roche Inc. (Nutley, NJ) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RG1662
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RG1662 | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| RG1662 | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| RG1662 | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| RG1662 | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| RG1662 | Hong Kong | HK1249728 | 2036-05-05 | See Plans and Pricing |
| RG1662 | Japan | JP2019520866 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
